Yes to Adjuvant Chemotherapy in EGFR Mutated NSCLC
During ELCC23, a controversial session was held where opponents debated the efficacy of adjuvant chemotherapy for patients with EGFR-mutated NSCLC. Listen to the ”YES” opponent Benjamin Besse from the Gustave Roussy Cancer Campus in France, summarizing his arguments from the session in favor of adjuvant chemotherapy.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
